Sequential Eribulin vs Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients With Operable HER2-Negative Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Oncologist
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients With Operable HER2-Negative Breast Cancer
Oncologist 2020 Nov 03;[EPub Ahead of Print], B Lim, J Song, NK Ibrahim, KB Koenig, M Chavez-MacGregor, JE Ensor, JS Gomez, S Krishnamurthy, AS Caudle, SF Shaitelman, GJ Whitman, V ValeroFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.